ARTICLE | Clinical News
Vraylar cariprazine regulatory update
September 28, 2015 7:00 AM UTC
FDA approved an NDA from Allergan for Vraylar cariprazine to treat schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. The company plans to launch ...